Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners and 3 distinct art units.
JASON MICHAEL NOLAN is the busiest examiner, responsible for 1 pending office action. The spread across 3 art units suggests technical variety in their pharmaceutical research filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOLAN, JASON MICHAEL | 1 | 66.5% | -27.8% |
| SULLIVAN, DENNIS JOHN | 1 | 57.3% | +49.1% |
| BREDEFELD, RACHAEL EVA | 1 | 27.4% | +35.0% |
| JOHNSON, TIRONE DEREK | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549186 | FURAN FUSED RING-SUBSTITUTED GLUTARIMIDE COMPOUND | BREDEFELD, RACHAEL EVA | — |
| 18280248 | ANTIBODY AGAINST NKP46 AND APPLICATION THEREOF | JOHNSON, TIRONE DEREK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18289007 | BINDING MOLECULE AGAINST DLL3 AND USE THEREOF | SULLIVAN, DENNIS JOHN | — |
| 18549186 | FURAN FUSED RING-SUBSTITUTED GLUTARIMIDE COMPOUND | BREDEFELD, RACHAEL EVA | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 3786 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18848394 | ENPP1 INHIBITOR | NOLAN, JASON MICHAEL | — | §112 | Non-Final OA | — | Pending | Sep 18, 2024 |
| 18289007 | BINDING MOLECULE AGAINST DLL3 AND USE THEREOF | SULLIVAN, DENNIS JOHN | 1642 | §112DP | Non-Final OA | — | Pending | Oct 31, 2023 |
| 18549186 | FURAN FUSED RING-SUBSTITUTED GLUTARIMIDE COMPOUND | BREDEFELD, RACHAEL EVA | 3786 | §103§112 | Non-Final OA | — | Pending | Sep 06, 2023 |
| 18280248 | ANTIBODY AGAINST NKP46 AND APPLICATION THEREOF | JOHNSON, TIRONE DEREK | 1675 | §112 | Non-Final OA | — | Pending | Sep 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial